{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:40:56Z","timestamp":1789656056608,"version":"4.0.1"},"reference-count":237,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Primary biliary cholangitis (PBC) is a heterogeneous autoimmune liver disease in which clinical presentation, disease progression, and response to therapy vary markedly from patient to patient. This heterogeneity reflects its complex, multifactorial, and not-completely elucidated pathogenesis. Currently, serological markers are available to non-invasively diagnose PBC, reserving liver biopsy for selected cases with atypical presentations or diagnostic uncertainty. Anyway, the accurate non-invasive prediction of liver-related and non-liver-related (i.e., extra-hepatic, including pruritus) outcomes remains an open challenge, as well as an urgent need, considering the great variability in clinical course and prognosis reported in PBC patients. Moreover, although ursodeoxycholic acid (UDCA) remains the standard first-line treatment, not all individuals respond equally, either in terms of therapeutic efficacy or timing of biochemical improvement. This further variability in treatment response underscores the inadequacy of uniform management approaches and reinforces the urgent need for personalized medicine, where treatment decisions are guided by patient-specific biological and clinical parameters. In this scenario, the identification and validation of non-invasive predictive biomarkers capable of detecting early therapeutic responsiveness are pivotal for optimizing care pathways. Finally, a growing portion of patients show an insufficient UDCA response or are UDCA intolerant, making the identification of novel strategies of care an urgent need. Concerning this, very recently, new therapeutic options beyond UDCA targeting, among the other pathways, bile acid metabolism (including the modern Peroxisome Proliferator-Activated Receptor agonists), immune regulation, and fibrogenesis, have expanded the treatment landscape. In the Era of Precision Medicine, these diagnostic, prognostic, and therapeutic innovations, by reflecting the complexity of PBC pathogenesis, underline the cruciality of a patient-tailored strategy to improve outcomes and mitigate disease progression. The present review reports recent advances, highlights ongoing challenges, and outlines future perspectives in the management of PBC.<\/jats:p>","DOI":"10.3390\/jpm15120597","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:37:02Z","timestamp":1764952622000},"page":"597","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-9019","authenticated-orcid":false,"given":"Mario","family":"Romeo","sequence":"first","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiammetta","family":"Di Nardo","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5473-3440","authenticated-orcid":false,"given":"Claudio","family":"Basile","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2392-3539","authenticated-orcid":false,"given":"Carmine","family":"Napolitano","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7600-290X","authenticated-orcid":false,"given":"Paolo","family":"Vaia","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia De","family":"Gregorio","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9705-0037","authenticated-orcid":false,"given":"Luigi Di","family":"Puorto","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4150-4722","authenticated-orcid":false,"given":"Mattia","family":"Indipendente","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-815X","authenticated-orcid":false,"given":"Marcello","family":"Dallio","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-0793","authenticated-orcid":false,"given":"Alessandro","family":"Federico","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.32074\/1591-951X-245","article-title":"Autoimmune Biliary Diseases: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cld.2018.03.001","article-title":"Changes in the Epidemiology of Primary Biliary Cholangitis","volume":"22","author":"Lleo","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cld.2022.06.008","article-title":"Primary Biliary Cholangitis in Males: Pathogenesis, Clinical Presentation, and Prognosis","volume":"26","author":"Shaker","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary Biliary Cirrhosis in Monozygotic and Dizygotic Twins: Genetics, Epigenetics, and Environment","volume":"127","author":"Selmi","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jhep.2021.04.055","article-title":"An International Genome-Wide Meta-Analysis of Primary Biliary Cholangitis: Novel Risk Loci and Candidate Drugs","volume":"75","author":"Cordell","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.dld.2021.04.010","article-title":"Novel HLA-DRB1 Alleles Contribute Risk for Disease Susceptibility in Primary Biliary Cholangitis","volume":"54","author":"Li","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0035-1567831","article-title":"Genome-Wide Association Studies in Primary Biliary Cirrhosis","volume":"35","author":"Gulamhusein","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6890423","DOI":"10.1155\/2021\/6890423","article-title":"MicroRNA-34a Promotes EMT and Liver Fibrosis in Primary Biliary Cholangitis by Regulating TGF-\u03921\/Smad Pathway","volume":"2021","author":"Pan","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-981-15-3449-2_10","article-title":"Epigenetics of Primary Biliary Cholangitis","volume":"1253","author":"Li","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0034-1383726","article-title":"Environmental Factors in Primary Biliary Cirrhosis","volume":"34","author":"Juran","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.it.2009.05.006","article-title":"The Role of Environmental Factors in Primary Biliary Cirrhosis","volume":"30","author":"Selmi","year":"2009","journal-title":"Trends Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jhep.2018.06.027","article-title":"Identification of a Xenobiotic as a Potential Environmental Trigger in Primary Biliary Cholangitis","volume":"69","author":"Probert","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.15403\/jgld-181","article-title":"Association between Smoking and Risk of Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis","volume":"28","author":"Wijarnpreecha","year":"2019","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4103\/ijmr.IJMR_639_19","article-title":"Smoking & Risk of Advanced Liver Fibrosis among Patients with Primary Biliary Cholangitis: A Systematic Review & Meta-Analysis","volume":"154","author":"Wijarnpreecha","year":"2021","journal-title":"Indian. J. Med. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.3748\/wjg.v18.i48.7141","article-title":"Role of Autoimmunity in Primary Biliary Cirrhosis","volume":"18","author":"Shi","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4292\/wjgpt.v6.i3.32","article-title":"Primary Biliary Cirrhosis: From Bench to Bedside","volume":"6","author":"Kouroumalis","year":"2015","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.dld.2010.02.014","article-title":"Update on Primary Biliary Cirrhosis","volume":"42","author":"Invernizzi","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary Biliary Cholangitis: Pathogenesis and Therapeutic Opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Li, H., Guan, Y., Han, C., Zhang, Y., Liu, Q., Wei, W., and Ma, Y. (2021). The Pathogenesis, Models and Therapeutic Advances of Primary Biliary Cholangitis. Biomed. Pharmacother., 140.","DOI":"10.1016\/j.biopha.2021.111754"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis. J. Hepatol., 67, 145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.autrev.2014.01.041","article-title":"The Diagnosis of Primary Biliary Cirrhosis","volume":"13","author":"Bowlus","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","article-title":"APASL Clinical Practice Guidance: The Diagnosis and Management of Patients with Primary Biliary Cholangitis","volume":"16","author":"You","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3350\/kjhep.2011.17.3.173","article-title":"The Diagnosis and Treatment of Primary Biliary Cirrhosis","volume":"17","author":"Kim","year":"2011","journal-title":"Korean J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12072-016-9767-9","article-title":"Autoimmune Liver Diseases in the Asia-Pacific Region: Proceedings of APASL Symposium on AIH and PBC 2016","volume":"10","author":"Tanaka","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and Management of Primary Biliary Cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3748\/wjg.v29.i12.1795","article-title":"Role of Autoantibodies in the Clinical Management of Primary Biliary Cholangitis","volume":"29","author":"Rigopoulou","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_27","first-page":"145","article-title":"A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist","volume":"15","author":"Onofrio","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary Biliary Cholangitis: Epidemiology, Prognosis, and Treatment","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102578","DOI":"10.1016\/j.jaut.2020.102578","article-title":"Primary Biliary Cholangitis with Normal Alkaline Phosphatase: A Neglected Clinical Entity Challenging Current Guidelines","volume":"116","author":"Stirnimann","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC Primary Biliary Cholangitis Treatment and Management Guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"ref_31","first-page":"736","article-title":"Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)","volume":"11","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.3748\/wjg.v29.i34.5075","article-title":"Role of Biochemical Markers and Autoantibodies in Diagnosis of Early-Stage Primary Biliary Cholangitis","volume":"29","author":"Zhu","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5005\/jp-journals-10018-1150","article-title":"A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature","volume":"5","author":"Begum","year":"2015","journal-title":"Euroasian J. Hepato-Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e36039","DOI":"10.1097\/MD.0000000000036039","article-title":"Diagnostic Value of Anti-Mitochondrial Antibody in Patients with Primary Biliary Cholangitis: A Systemic Review and Meta-Analysis","volume":"102","author":"Xu","year":"2023","journal-title":"Medicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cld.2018.03.008","article-title":"Liver Biopsy in Primary Biliary Cholangitis: Indications and Interpretation","volume":"22","author":"Tan","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/apt.15060","article-title":"Trends in Liver Transplantation for Primary Biliary Cholangitis in Europe over the Past Three Decades","volume":"49","author":"Harms","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/s-2008-1040506","article-title":"Liver Transplantation for Primary Biliary Cirrhosis","volume":"9","author":"Tzakis","year":"1989","journal-title":"Semin. Liver Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary Biliary Cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/livers4040045","article-title":"Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life\u2014Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?","volume":"4","author":"Dallio","year":"2024","journal-title":"Livers"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/MEG.0000000000001791","article-title":"Relationship between Osteoporosis, Sarcopenia, Vertebral Fracture, and Osteosarcopenia in Patients with Primary Biliary Cholangitis","volume":"33","author":"Saeki","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cld.867","article-title":"Primary Biliary Cholangitis: A Brief Overview","volume":"15","author":"Louie","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaut.2018.10.024","article-title":"Prognostic Models in Primary Biliary Cholangitis","volume":"95","author":"Cristoferi","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhepr.2019.05.005","article-title":"New Treatments\/Targets for Primary Biliary Cholangitis","volume":"1","author":"Corpechot","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Koky, T., Drazilova, S., Janicko, M., Toporcerova, D., Gazda, J., and Jarcuska, P. (2025). Early Assessment of Treatment Response in Primary Biliary Cholangitis: Key to Timely Management. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-04138-w"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase","volume":"115","author":"Harms","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2468-1253(25)00025-1","article-title":"Primary Biliary Cholangitis and the Narrowing Gap towards Optimal Disease Control","volume":"10","author":"Lleo","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17562848241265782","DOI":"10.1177\/17562848241265782","article-title":"The Treatment of Primary Biliary Cholangitis: From Shadow to Light","volume":"17","author":"Sylvia","year":"2024","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.hepres.2005.09.029","article-title":"Hepatoprotective Bile Acid \u201cursodeoxycholic Acid (UDCA)\u201d Property and Difference as Bile Acids","volume":"33","author":"Ishizaki","year":"2005","journal-title":"Hepatol. Res."},{"key":"ref_50","first-page":"D6970","article-title":"Ursodeoxycholic acid: History and clinical implications","volume":"166","author":"Beuers","year":"2022","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"G735","DOI":"10.1152\/ajpgi.90321.2008","article-title":"Ursodeoxycholic Acid Stimulates Nrf2-Mediated Hepatocellular Transport, Detoxification, and Antioxidative Stress Systems in Mice","volume":"295","author":"Okada","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cld.2022.06.012","article-title":"Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies","volume":"26","author":"Liu","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_54","first-page":"759","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Ursodeoxycholic Acid in Primary Biliary Cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-Term Effects of Ursodeoxycholic Acid in Primary Biliary Cirrhosis: Results of a Double-Blind Controlled Multicentric Trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver","volume":"32","author":"Bruguera","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic Acid Therapy and Liver Transplant-Free Survival in Patients with Primary Biliary Cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2468-1253(19)30343-7","article-title":"Current and Potential Treatments for Primary Biliary Cholangitis","volume":"5","author":"Shah","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis in Primary Biliary Cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved Prognosis of Patients with Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cld.2018.03.003","article-title":"Current Treatment Options for Primary Biliary Cholangitis","volume":"22","author":"Wong","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/00365521.2019.1606931","article-title":"Biochemical Response to Ursodeoxycholic Acid among PBC Patients: A Nationwide Population-Based Study","volume":"54","author":"Lund","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13643-024-02460-0","article-title":"Optimal Drug Regimens for Improving ALP Biochemical Levels in Patients with Primary Biliary Cholangitis Refractory to UDCA: A Systematic Review and Bayesian Network Meta-Analysis","volume":"13","author":"Lin","year":"2024","journal-title":"Syst. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Marenco-Flores, A., Rojas Amaris, N., Kahan, T., Sierra, L., Barba Bernal, R., Medina-Morales, E., Goyes, D., Patwardhan, V., and Bonder, A. (2024). The External Validation of GLOBE and UK-PBC Risk Scores for Predicting Ursodeoxycholic Acid Treatment Response in a Large U.S. Cohort of Primary Biliary Cholangitis Patients. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154497"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/1751-2980.13359","article-title":"GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients with Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate","volume":"26","author":"Li","year":"2025","journal-title":"J. Dig. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide Combined with UDCA to Improve Liver Histology in Primary Biliary Cirrhosis: A Three-Year Randomized Trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral Budesonide and Ursodeoxycholic Acid for Treatment of Primary Biliary Cirrhosis: Results of a Prospective Double-Blind Trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e936387","DOI":"10.12659\/AJCR.936387","article-title":"A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn\u2019s Ileitis Following the Suspension of Ursodeoxycholic Acid","volume":"23","author":"Romeo","year":"2022","journal-title":"Am. J. Case Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early- and Late-Stage Primary Biliary Cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A Placebo-Controlled Randomised Trial of Budesonide for PBC Following an Insufficient Response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/17474124.2016.1216784","article-title":"Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis","volume":"10","author":"Jones","year":"2016","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1080\/14656566.2016.1218471","article-title":"Obeticholic Acid for the Treatment of Primary Biliary Cholangitis","volume":"17","author":"Ali","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.32405","article-title":"Mechanisms and Molecules: What Are the Treatment Targets for Primary Biliary Cholangitis?","volume":"76","author":"Mayo","year":"2022","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17512433.2015.1092381","article-title":"Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis","volume":"9","author":"Trivedi","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic Acid: First Global Approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S2468-1253(19)30084-6","article-title":"Long-Term Outcomes with Obeticholic Acid in Primary Biliary Cholangitis: Reassuring, but Still an Itch We Need to Scratch","volume":"4","author":"Eaton","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14728214.2020.1751814","article-title":"Emerging Drugs for the Treatment of Primary Biliary Cholangitis","volume":"25","author":"Phaw","year":"2020","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Floreani, A., Gabbia, D., and De Martin, S. (2022). Obeticholic Acid for Primary Biliary Cholangitis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102464"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","article-title":"COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis with Placebo and External Controls","volume":"120","author":"Kowdley","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary Biliary Cholangitis Drug Evaluation and Regulatory Approval: Where Do We Go from Here?","volume":"80","author":"Jones","year":"2024","journal-title":"Hepatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"154338","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The Role of Peroxisome Proliferator-Activated Receptors (PPAR) in Immune Responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and Cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1080\/14656566.2024.2406268","article-title":"Revisiting PPAR Agonists: Novel Perspectives in the Treatment of Primary Biliary Cholangitis","volume":"25","author":"Chen","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR Agonists for the Treatment of Primary Biliary Cholangitis: Old and New Tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J. Transl. Autoimmun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.24148","article-title":"Nuclear Receptors in Liver Disease","volume":"53","author":"Wagner","year":"2011","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2004.09.110","article-title":"PPARalpha Ligands Activate Antioxidant Enzymes and Suppress Hepatic Fibrosis in Rats","volume":"324","author":"Toyama","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"704","DOI":"10.5604\/01.3001.0010.2709","article-title":"Fibrates for Primary Biliary Cholangitis: What\u2019s All the Hype?","volume":"16","author":"Levy","year":"2017","journal-title":"Ann. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11901-019-00455-3","article-title":"The Role of Fibrates in Primary Biliary Cholangitis","volume":"18","author":"Corpechot","year":"2019","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_89","unstructured":"(2025, November 01). Bezafibrate for Primary Biliary Cholangitis: Efficacy, Safety, and Efficiency of an off-Label Use Protocol in Real-World Practice\u2014Cerca Con Google. Available online: https:\/\/ejhp.bmj.com\/content\/32\/Suppl_1\/A129.2."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1111\/j.1872-034X.2007.00232.x","article-title":"Fibrate for Treatment of Primary Biliary Cirrhosis","volume":"37","author":"Iwasaki","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of Bezafibrate with Transplant-Free Survival in Patients with Primary Biliary Cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients with Primary Biliary Cirrhosis and Dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha\/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A Randomized Placebo-Controlled Trial of Elafibranor in Patients with Primary Biliary Cholangitis and Incomplete Response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-024-02075-8","article-title":"Elafibranor: First Approval","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a Selective PPAR-\u03b4 Agonist, in Patients with Primary Biliary Cholangitis with an Inadequate Response to Ursodeoxycholic Acid: A Double-Blind, Randomised, Placebo-Controlled, Phase 2, Proof-of-Concept Study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A Phase II, Randomized, Open-Label, 52-Week Study of Seladelpar in Patients with Primary Biliary Cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar Efficacy and Safety at 3 Months in Patients with Primary Biliary Cholangitis: ENHANCE, a Phase 3, Randomized, Placebo-Controlled Study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/apt.17755","article-title":"Open-Label, Clinical Trial Extension: Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis","volume":"59","author":"Mayo","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/10600280251320069","article-title":"Seladelpar for the Treatment of Primary Biliary Cholangitis","volume":"59","author":"Khoury","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1515\/jbcpp-2024-0124","article-title":"Seladelpar: A Comprehensive Review of Its Clinical Efficacy and Safety in the Treatment of Primary Biliary Cholangitis","volume":"36","author":"Shukla","year":"2025","journal-title":"J. Basic. Clin. Physiol. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-024-02114-4","article-title":"Seladelpar: First Approval","volume":"84","author":"Hoy","year":"2024","journal-title":"Drugs"},{"key":"ref_108","unstructured":"(2025, August 28). Ipsen A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 Mg on Long-Term Clinical Outcomes in Adult Participants with Primary Biliary Cholangitis (PBC), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06016842."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Levy, C., Trivedi, P.J., Kowdley, K.V., Gordon, S.C., Bowlus, C.L., Londo\u00f1o, M.C., Hirschfield, G.M., Gulamhusein, A., Lawitz, E.J., and Vierling, J.M. (2025). Long-Term Efficacy and Safety of Selective PPAR\u03b4 Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. Am. J. Gastroenterol.","DOI":"10.14309\/ajg.0000000000003603"},{"key":"ref_110","first-page":"8","article-title":"Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients with Primary Biliary Cholangitis: Pooled Interim Results for Up to 3 Years From the ASSURE Study","volume":"20","author":"Eric","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/dia.2013.0253","article-title":"A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4\u2009Mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)","volume":"16","author":"Jani","year":"2014","journal-title":"Diabetes Technol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-Concept Study to Evaluate the Safety and Efficacy of Saroglitazar in Patients with Primary Biliary Cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e00327","DOI":"10.14309\/ctg.0000000000000327","article-title":"A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients with Primary Biliary Cholangitis","volume":"12","author":"Vuppalanchi","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cpt.3450","article-title":"Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis with Hepatic Impairment and Participants with Renal Impairment","volume":"117","author":"Vuppalanchi","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"101945","DOI":"10.1016\/j.aohep.2025.101945","article-title":"Primary Biliary Cholangitis Has the Worst Quality of Life Indicators among the Autoimmune Liver Diseases: A United States Cohort","volume":"30","author":"Sierra","year":"2025","journal-title":"Ann. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.21953","article-title":"Quality of Life and Everyday Activities in Patients with Primary Biliary Cirrhosis","volume":"46","author":"Selmi","year":"2007","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/00365521.2021.2010800","article-title":"Health-Related Quality of Life Questionnaires Used in Primary Biliary Cholangitis: A Systematic Review","volume":"57","author":"Ai","year":"2022","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Kanda, T., Sasaki-Tanaka, R., Kimura, N., Abe, H., Yoshida, T., Hayashi, K., Sakamaki, A., Yokoo, T., Kamimura, H., and Tsuchiya, A. (2025). Pruritus in Chronic Cholestatic Liver Diseases, Especially in Primary Biliary Cholangitis: A Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26051883"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-023-07862-z","article-title":"Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review","volume":"68","author":"Smith","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cld.2022.06.009","article-title":"Evaluation and Management of Pruritus in Primary Biliary Cholangitis","volume":"26","author":"Kremer","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-022-00687-7","article-title":"Mechanisms of Pruritus in Cholestasis: Understanding and Treating the Itch","volume":"20","author":"Beuers","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and Liver Dysfunction with Rifampicin Therapy for Pruritus in Primary Biliary Cirrhosis","volume":"50","author":"Prince","year":"2002","journal-title":"Gut"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1345\/aph.18115","article-title":"Opioid Antagonists in the Treatment of Pruritus from Cholestatic Liver Disease","volume":"32","author":"Terra","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cld.2018.03.005","article-title":"Understanding and Treating Pruritus in Primary Biliary Cholangitis","volume":"22","author":"Carrion","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"744.e1","DOI":"10.1016\/j.amjmed.2017.01.037","article-title":"Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review","volume":"130","author":"Trivedi","year":"2017","journal-title":"Am. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1574887114666190328130720","article-title":"Comparison of Sertraline with Rifampin in the Treatment of Cholestatic Pruritus: A Randomized Clinical Trial","volume":"14","author":"Ataei","year":"2019","journal-title":"Rev. Recent. Clin. Trials"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.21037\/apm-21-1304","article-title":"Fibrates for the Treatment of Pruritus in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis","volume":"10","author":"Shen","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar Treatment Reduces IL-31 and Pruritus in Patients with Primary Biliary Cholangitis","volume":"80","author":"Kremer","year":"2024","journal-title":"Hepatology"},{"key":"ref_129","unstructured":"Hirschfield, G.M., Bowlus, C.L., Jones, D.E.J., Kremer, A.E., Mayo, M.J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., and Mac\u00edas-Rodr\u00edguez, R.U. (2025). Linerixibat in Patients with Primary Biliary Cholangitis and Cholestatic Pruritus (GLISTEN): A Randomised, Multicentre, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Gastroenterol. Hepatol., S2468-1253(25)00192-X."},{"key":"ref_130","first-page":"e0635","article-title":"Pervasive Role of Pruritus in Impaired Quality of Life in Patients with Primary Biliary Cholangitis: Data from the GLIMMER Study","volume":"9","author":"Smith","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/liv.15782","article-title":"Golexanolone Improves Fatigue, Motor Incoordination and Gait and Memory in Rats with Bile Duct Ligation","volume":"44","author":"Arenas","year":"2024","journal-title":"Liver Int."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined Analysis of Randomized Controlled Trials of Ursodeoxycholic Acid in Primary Biliary Cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-Term Ursodeoxycholic Acid Delays Histological Progression in Primary Biliary Cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of Hepatocellular Carcinoma Risk in Primary Biliary Cirrhosis: A Multicentre International Study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/hep.26176","article-title":"Incidence of and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis: National Data from Japan","volume":"57","author":"Harada","year":"2013","journal-title":"Hepatology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.06.006","article-title":"Risk Stratification and Prognostic Modelling in Primary Biliary Cholangitis","volume":"34\u201335","author":"Goet","year":"2018","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Lleo, A., Jepsen, P., Morenghi, E., Carbone, M., Moroni, L., Battezzati, P.M., Podda, M., Mackay, I.R., Gershwin, M.E., and Invernizzi, P. (2016). Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. Sci. Rep., 6.","DOI":"10.1038\/srep25906"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1016\/S0168-8278(15)31380-5","article-title":"P1184: Age, Bilirubin and Albumin, Regardless of Sex, Are the Strongest Independent Predictors of Biochemical Response and Transplantation-Free Survival in Patients with Primary Biliary Cirrhosis","volume":"62","author":"Cheung","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising Risk Stratification in Primary Biliary Cirrhosis: AST\/Platelet Ratio Index Predicts Outcome Independent of Ursodeoxycholic Acid Response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment Prediction of Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis: Development and Validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/0016-5085(90)91091-J","article-title":"Diminished Survival in Asymptomatic Primary Biliary Cirrhosis. A Prospective Study","volume":"98","author":"Balasubramaniam","year":"1990","journal-title":"Gastroenterology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and Symptom Progression in a Geographically Based Cohort of Patients with Primary Biliary Cirrhosis: Follow-up for up to 28 Years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(96)04410-8","article-title":"Natural History of Early Primary Biliary Cirrhosis","volume":"348","author":"Metcalf","year":"1996","journal-title":"Lancet"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1572-0241.1999.00770.x","article-title":"Asymptomatic Primary Biliary Cirrhosis: A Study of Its Natural History and Prognosis","volume":"94","author":"Springer","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/liv.12560","article-title":"Fatigue and Pruritus at Onset Identify a More Aggressive Subset of Primary Biliary Cirrhosis","volume":"35","author":"Quarneti","year":"2015","journal-title":"Liver Int."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2010.05.026","article-title":"The Independent Effects of Fatigue and UDCA Therapy on Mortality in Primary Biliary Cirrhosis: Results of a 9 Year Follow-Up","volume":"53","author":"Jones","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Martini, F., Balducci, D., Mancinelli, M., Buzzanca, V., Fracchia, E., Tarantino, G., Benedetti, A., Marzioni, M., and Maroni, L. (2023). Risk Stratification in Primary Biliary Cholangitis. J. Clin. Med., 12.","DOI":"10.20944\/preprints202307.1192.v1"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"102453","DOI":"10.1016\/j.clinre.2024.102453","article-title":"Alkaline Phosphatase and Liver Fibrosis at Diagnosis Are Associated with Deep Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis","volume":"48","author":"Fucuta","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients with Primary Biliary Cirrhosis: An International Follow-up Study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus Deep Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis: To What Extent and under What Conditions Is Normal Alkaline Phosphatase Level Associated with Complication-Free Survival Gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/liv.15592","article-title":"Optimizing Therapy in Primary Biliary Cholangitis: Alkaline Phosphatase at Six Months Identifies One-Year Non-Responders and Predicts Survival","volume":"43","author":"Ioannou","year":"2023","journal-title":"Liver Int."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.20.2.137","article-title":"Serum Bilirubin: A Prognostic Factor in Primary Biliary Cirrhosis","volume":"20","author":"Shapiro","year":"1979","journal-title":"Gut"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cld.2022.06.005","article-title":"Prognostic Scoring Systems in Primary Biliary Cholangitis","volume":"26","author":"Scaravaglio","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1386-6346(99)00005-4","article-title":"Elevation of Serum Gamma-Glutamyl Transpeptidase Precedes That of Alkaline Phosphatase in the Early Stages of Primary Biliary Cirrhosis","volume":"14","author":"Matsuo","year":"1999","journal-title":"Hepatol. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1872-034X.2011.00782.x","article-title":"Biochemical Response to Ursodeoxycholic Acid Predicts Long-Term Outcome in Japanese Patients with Primary Biliary Cirrhosis","volume":"41","author":"Azemoto","year":"2011","journal-title":"Hepatol. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients","volume":"101","author":"Schalm","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2024.10.020","article-title":"Noninvasive Assessment of Portal Hypertension in Patients with Primary Biliary Cholangitis Is Affected by Severity of Cholestasis","volume":"23","author":"Calvaruso","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/hepr.12423","article-title":"Autoantibody Status and Histological Variables Influence Biochemical Response to Treatment and Long-Term Outcomes in Japanese Patients with Primary Biliary Cirrhosis","volume":"45","author":"Nakamura","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"101121","DOI":"10.1016\/j.aohep.2023.101121","article-title":"Anti-Gp210-Positive Primary Biliary Cholangitis: The Dilemma of Clinical Treatment and Emerging Mechanisms","volume":"28","author":"Wang","year":"2023","journal-title":"Ann. Hepatol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"9121207","DOI":"10.1155\/2019\/9121207","article-title":"Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis","volume":"2019","author":"Huang","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to Gp210 and Understanding Risk in Patients with Primary Biliary Cholangitis","volume":"40","author":"Haldar","year":"2021","journal-title":"Liver Int."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-Gp210 and Anti-Centromere Antibodies Are Different Risk Factors for the Progression of Primary Biliary Cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and Clinical Impact of Antinuclear Antibodies in Primary Biliary Cirrhosis","volume":"98","author":"Muratori","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.clinre.2020.03.026","article-title":"Treatment of Primary Biliary Cholangitis with Ursodeoxycholic Acid, Prednisolone and Immunosuppressants in Patients Not Responding to Ursodeoxycholic Acid Alone and the Prognostic Indicators","volume":"44","author":"Qian","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The Risk Predictive Values of UK-PBC and GLOBE Scoring System in Chinese Patients with Primary Biliary Cholangitis: The Additional Effect of Anti-Gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0034-1383732","article-title":"Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis","volume":"34","author":"Nakamura","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1746.1998.01553.x","article-title":"Autoantibodies against a 210 kDa Glycoprotein of the Nuclear Pore Complex as a Prognostic Marker in Patients with Primary Biliary Cirrhosis","volume":"13","author":"Itoh","year":"1998","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/08916934.2013.801461","article-title":"Clinical Significance of the Fluctuation of Primary Biliary Cirrhosis-Related Autoantibodies during the Course of the Disease","volume":"46","author":"Gatselis","year":"2013","journal-title":"Autoimmunity"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.14309\/ajg.0000000000000690","article-title":"Novel Anti-Hexokinase 1 Antibodies Are Associated with Poor Prognosis in Patients with Primary Biliary Cholangitis","volume":"115","author":"Reig","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1309\/AJCPQV4A7QAEEFEV","article-title":"The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis","volume":"144","author":"Tana","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-008-0150-6","article-title":"The Value of Antinuclear Antibodies in Primary Biliary Cirrhosis","volume":"8","author":"Gao","year":"2008","journal-title":"Clin. Exp. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.dld.2024.12.024","article-title":"The Prognostic Value of Anti-Gp210 and Anti-Centromere Antibodies in Patients with Primary Biliary Cholangitis: Enhancing the Prognostic Utility on the GLOBE Scoring System","volume":"57","author":"Ding","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/liv.12690","article-title":"Anti-Kelch-like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis","volume":"35","author":"Norman","year":"2015","journal-title":"Liver Int."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"502225","DOI":"10.1016\/j.gastrohep.2024.502225","article-title":"The Phenotypic Landscape of Primary Biliary Cholangitis and Autoimmune Hepatitis Variants","volume":"48","author":"Bolis","year":"2025","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2018.10.001","article-title":"Factors Associated with Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival","volume":"156","author":"Hansen","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1111\/j.1872-034X.2007.00247.x","article-title":"Biliary Innate Immunity and Cholangiopathy","volume":"37","author":"Harada","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of Chronic Nonsuppurative Destructive Cholangitis (Syndrome of Primary Biliary Cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch. A Pathol. Anat. Histol."},{"key":"ref_181","first-page":"1257","article-title":"Primary Biliary Cirrhosis","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc. R. Soc. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MCG.0b013e31827234e4","article-title":"Application and Validation of a New Histologic Staging and Grading System for Primary Biliary Cirrhosis","volume":"47","author":"Harada","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/liv.12620","article-title":"Primary Biliary Cirrhosis: Proposal for a New Simple Histological Scoring System","volume":"35","author":"Wendum","year":"2015","journal-title":"Liver Int."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/hep.1840080127","article-title":"Serum Hyaluronate in Primary Biliary Cirrhosis\u2014A Biochemical Marker for Progressive Liver Damage","volume":"8","author":"Nyberg","year":"1988","journal-title":"Hepatology"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.22517","article-title":"Prediction of Clinical Outcomes in Primary Biliary Cirrhosis by Serum Enhanced Liver Fibrosis Assay","volume":"48","author":"Mayo","year":"2008","journal-title":"Hepatology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e27403","DOI":"10.1097\/MD.0000000000027403","article-title":"Enhanced Liver Fibrosis Score as a Surrogate of Liver-Related Complications and Mortality in Primary Biliary Cholangitis","volume":"100","author":"Fujinaga","year":"2021","journal-title":"Medicine"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/j.gastro.2008.07.019","article-title":"Portal Hypertension and Primary Biliary Cirrhosis: Effect of Long-Term Ursodeoxycholic Acid Treatment","volume":"135","author":"Huet","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e13431","DOI":"10.1097\/MD.0000000000013431","article-title":"Increased Red Cell Width Distribution to Lymphocyte Ratio Is a Predictor of Histologic Severity in Primary Biliary Cholangitis","volume":"97","author":"Meng","year":"2018","journal-title":"Medicine"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/00365513.2018.1449011","article-title":"Red Blood Cell Distribution Width to Platelet Ratio Levels in Assessment of Histologic Severity in Patients with Primary Biliary Cholangitis","volume":"78","author":"Jiang","year":"2018","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3748\/wjg.v30.i7.685","article-title":"Red Cell Distribution Width\/Platelet Ratio Estimates the 3-Year Risk of Decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Cirrhosis","volume":"30","author":"Dallio","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/MEG.0000000000000637","article-title":"The Relationship between Liver Histology and Noninvasive Markers in Primary Biliary Cirrhosis","volume":"28","author":"Olmez","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e3114","DOI":"10.1097\/MD.0000000000003114","article-title":"Red Blood Cell Distribution Width to Platelet Ratio Is Related to Histologic Severity of Primary Biliary Cirrhosis","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.dld.2015.10.024","article-title":"Assessment of Liver Fibrosis in Primary Biliary Cholangitis: Comparison between Indirect Serum Markers and Fibrosis Morphometry","volume":"48","author":"Stasi","year":"2016","journal-title":"Dig. Liver Dis."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/MEG.0000000000000463","article-title":"Increased Mean Platelet Volume Is Related to Histologic Severity of Primary Biliary Cirrhosis","volume":"27","author":"Tahtaci","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e9843","DOI":"10.1097\/MD.0000000000009843","article-title":"Platelet Count to Spleen Thickness Ratio Is Related to Histologic Severity of Primary Biliary Cholangitis","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014Renewing Consensus in Portal Hypertension","volume":"76","author":"Bosch","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hepr.12595","article-title":"Impact of Serum Wisteria Floribunda Agglutinin Positive Mac-2-Binding Protein and Serum Interferon-\u03b3-Inducible Protein-10 in Primary Biliary Cirrhosis","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver Stiffness Measurement by Vibration-Controlled Transient Elastography Improves Outcome Prediction in Primary Biliary Cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/hepr.12861","article-title":"Comparison between Real-Time Tissue Elastography and Vibration-Controlled Transient Elastography for the Assessment of Liver Fibrosis and Disease Progression in Patients with Primary Biliary Cholangitis","volume":"47","author":"Koizumi","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2021). EASL Clinical Practice Guidelines on Non-Invasive Tests for Evaluation of Liver Disease Severity and Prognosis\u20142021 Update. J. Hepatol., 75, 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.cgh.2024.06.035","article-title":"Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis","volume":"22","author":"Lam","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"100952","DOI":"10.1016\/j.jhepr.2023.100952","article-title":"Spleen Stiffness Measurement Predicts Decompensation and Rules out High-Risk Oesophageal Varices in Primary Biliary Cholangitis","volume":"6","author":"Rigamonti","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/jmri.23731","article-title":"Magnetic Resonance Elastography of Liver: Technique, Analysis, and Clinical Applications","volume":"37","author":"Venkatesh","year":"2013","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mri.2014.10.003","article-title":"Comparison of the Diagnostic Accuracies of Magnetic Resonance Elastography and Transient Elastography for Hepatic Fibrosis","volume":"33","author":"Ichikawa","year":"2015","journal-title":"Magn. Reson. Imaging"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cgh.2014.09.046","article-title":"Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-Analysis of Individual Participant Data","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1053\/jlts.2000.6503","article-title":"Adaptation of the Mayo Primary Biliary Cirrhosis Natural History Model for Application in Liver Transplant Candidates","volume":"6","author":"Kim","year":"2000","journal-title":"Liver Transpl."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in Primary Biliary Cirrhosis: Model for Decision Making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"ref_208","first-page":"126","article-title":"Primary Biliary Cirrhosis: Prediction of Short-Term Survival Based on Repeated Patient Visits","volume":"20","author":"Murtaugh","year":"1994","journal-title":"Hepatology"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The Prognostic Importance of Clinical and Histologic Features in Asymptomatic and Symptomatic Primary Biliary Cirrhosis","volume":"308","author":"Roll","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial Effect of Azathioprine and Prediction of Prognosis in Primary Biliary Cirrhosis. Final Results of an International Trial","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of Liver Function in Patients with Hepatocellular Carcinoma: A New Evidence-Based Approach-the ALBI Grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/jgh.12938","article-title":"New Simple Prognostic Score for Primary Biliary Cirrhosis: Albumin-Bilirubin Score","volume":"30","author":"Chan","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A Model to Predict Poor Survival in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunts","volume":"31","author":"Malinchoc","year":"2000","journal-title":"Hepatology"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent Long-Term Survival in Patients with Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early Primary Biliary Cirrhosis: Biochemical Response to Treatment and Prediction of Long-Term Outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.medcli.2018.08.002","article-title":"Analysis of Predictive Response Scores to Treatment with Ursodeoxycholic Acid in Patients with Primary Biliary Cholangitis","volume":"152","author":"Brunet","year":"2019","journal-title":"Med. Clin."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.dld.2022.12.010","article-title":"Treatment Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis","volume":"55","author":"Gazda","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC Risk Scores: Derivation and Validation of a Scoring System for Long-Term Prediction of End-Stage Liver Disease in Primary Biliary Cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/hep.31810","article-title":"Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Na\u00efve Patients with Primary Biliary Cholangitis: A Dual Cut-Off Approach","volume":"74","author":"Cristoferi","year":"2021","journal-title":"Hepatology"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/liv.15141","article-title":"Machine Learning in Primary Biliary Cholangitis: A Novel Approach for Risk Stratification","volume":"42","author":"Gerussi","year":"2022","journal-title":"Liver Int."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12016-019-08731-2","article-title":"Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis","volume":"58","author":"Chen","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_224","first-page":"958","article-title":"Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis: From Bench to Bedside","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Lammert, C., Shin, A.S., Xu, H., Hemmerich, C., O\u2019Connell, T.M., and Chalasani, N. (2021). Short-Chain Fatty Acid and Fecal Microbiota Profiles Are Linked to Fibrosis in Primary Biliary Cholangitis. FEMS Microbiol. Lett., 368.","DOI":"10.1093\/femsle\/fnab038"},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Romeo, M., Dallio, M., Di Nardo, F., Napolitano, C., Vaia, P., Martinelli, G., Federico, P., Olivieri, S., Iodice, P., and Federico, A. (2025). The Role of the Gut-Biliary-Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications. J. Pers. Med., 15.","DOI":"10.3390\/jpm15040124"},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Zhou, Y.-J., Ying, G.-X., Dong, S.-L., Xiang, B., and Jin, Q.-F. (2023). Gut Microbial Profile of Treatment-Naive Patients with Primary Biliary Cholangitis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1126117"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"105368","DOI":"10.1016\/j.micinf.2024.105368","article-title":"Machine Learning-Based Characterization of the Gut Microbiome Associated with the Progression of Primary Biliary Cholangitis to Cirrhosis","volume":"26","author":"Wang","year":"2024","journal-title":"Microbes Infect."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"100504","DOI":"10.1016\/j.medj.2024.08.003","article-title":"Gut Microbiome Pattern Impacts Treatment Response in Primary Biliary Cholangitis","volume":"6","author":"Liu","year":"2025","journal-title":"Med"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Han, W., Song, T., Huang, Z., Liu, Y., Xu, B., and Huang, C. (2024). Distinct Signatures of Gut Microbiota and Metabolites in Primary Biliary Cholangitis with Poor Biochemical Response after Ursodeoxycholic Acid Treatment. Cell Biosci., 14.","DOI":"10.1186\/s13578-024-01253-1"},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Zhou, Z., Li, W., Wu, Y., Wang, T., Zhang, J., You, L., Li, H., Zheng, C., Gao, Y., and Sun, X. (2024). Bidirectional Mendelian Randomization Links Gut Microbiota to Primary Biliary Cholangitis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-79227-z"},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Dallio, M., Romeo, M., Cipullo, M., Ventriglia, L., Scognamiglio, F., Vaia, P., Iadanza, G., Coppola, A., and Federico, A. (2024). Systemic Oxidative Balance Reflects the Liver Disease Progression Status for Primary Biliary Cholangitis (Pbc): The Narcissus Fountain. Antioxidants, 13.","DOI":"10.3390\/antiox13040387"},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Jung, J.H., Lee, K.J., Park, S.W., Koh, D.H., and Lee, J. (2025). Point-of-Care Testing and Biomarkers in Biliary Diseases: Current Evidence and Future Directions. J. Clin. Med., 14.","DOI":"10.3390\/jcm14196724"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13075-023-03163-y","article-title":"Integrative Bioinformatics Analysis and Experimental Validation of Key Biomarkers for Risk Stratification in Primary Biliary Cholangitis","volume":"25","author":"Tian","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_235","first-page":"14","article-title":"The Evolving Use of Biochemical Markers in the Management of Primary Biliary Cholangitis: Discussion","volume":"17","author":"Kowdley","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Yang, J., Jiang, S., Fan, Q., Wen, D., Liu, Y., Wang, K., Yang, H., Guo, C., Zhou, X., and Guo, G. (2024). Prevalence and Effect on Prognosis of Sarcopenia in Patients with Primary Biliary Cholangitis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1346165"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.21037\/qims-24-553","article-title":"Mean Liver Density Independently Predicts Therapeutic Response and Liver-Related Mortality in Patients with Primary Biliary Cholangitis","volume":"14","author":"Wang","year":"2024","journal-title":"Quant. Imaging Med. Surg."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/12\/597\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:55:09Z","timestamp":1764953709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/12\/597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":237,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jpm15120597"],"URL":"https:\/\/doi.org\/10.3390\/jpm15120597","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}